Wednesday, 8 Oct 2025
  • About Us
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Subscribe
Brinks Report
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
  • 🔥
  • World
  • Business
  • Economy
  • Technology
  • Automobile
  • Entertainment
  • People
  • Sports
  • India
  • IPL
Font ResizerAa
Brinks ReportBrinks Report
Search
  • Featured
  • Money Matters
  • Business
  • IPL
  • Technology
  • Automobile
  • Entertainment
  • Sports
  • More
    • People
    • World
    • Health and Wellness
    • Horoscope
  • Today’s News
Have an existing account? Sign In
Follow US
© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.
Brinks Report > Blog > Business > Will Mounjaro Be the Game-Changer for Weight Loss and Diabetes in India?
Business

Will Mounjaro Be the Game-Changer for Weight Loss and Diabetes in India?

Dolon Mondal
Last updated: March 20, 2025 3:36 pm
Dolon Mondal
Share
Will mounjaro be the game-changer for weight loss and diabetes in india?
SHARE
Trulli

Mounjaro: A New Hope for Weight Loss and Diabetes Management in India

In a significant move for healthcare in India, Eli Lilly has launched Mounjaro, a revolutionary injectable drug designed to tackle obesity and type 2 diabetes. This much-anticipated drug is priced at INR 3,500 for a 2.5 mg vial and INR 4,375 for a 5 mg vial. It promises to be a game-changer for millions struggling with weight-related health issues.

What is Mounjaro? Mounjaro, also known as Tirzepatide, is a once-a-week prescription medication. It helps regulate appetite, reduce food intake, and decrease body weight.

Trulli

The drug works by activating both GIP and GLP-1 hormone receptors. These receptors play a crucial role in managing blood sugar levels and fat utilization. This dual action makes Mounjaro particularly effective for chronic weight management and improving glycemic control in adults with type 2 diabetes.

Why is This Launch Important?

India has the second-highest number of people with diabetes in the world, around 100 million. Obesity is a major risk factor for diabetes. It is connected to more than 200 health problems, including high blood pressure and heart disease. The arrival of Mounjaro gives new hope to people dealing with these issues

Also Read: New Hope for Cancer Patients! Zydus Lifesciences’ Apalutamide Tablets Approved by USFDA

Clinical Trials and Results

Mounjaro has been tested in two major global studies: SURMOUNT-1 and SURPASS. In the SURMOUNT-1 trial, people who took Mounjaro lost a lot of weight. At the highest dose, they lost an average of 21.8 kg. The SURPASS trials showed that Mounjaro also helps control blood sugar levels, which is very important for people with diabetes.

Commitment to India

Eli Lilly has set special prices for India to make sure more people can get this treatment. Winselow Tucker, who leads Lilly in India, said the company wants to work with the government and others to help people understand and manage obesity and diabetes better.

The launch of Mounjaro in India marks a significant step in addressing obesity and diabetes. With its proven results and affordable pricing, Mounjaro will help many people improve their health.

Also Read: Shilpa Medicare’s Stock Rises 10% on Cancer Therapy Deal with mAbTree

Image Slider
Image 1 Image 2 Image 3
TAGGED:diabetes treatmentEli LillyIndia healthcareMounjaroobesity managementSURMOUNT trialsSURPASS trialsTirzepatideweight-loss drug
Share This Article
Facebook Whatsapp Whatsapp Copy Link Print
What do you think?
Love0
Sad0
Happy0
Joy0
Sleepy0
Angry0
Surprise0
Previous Article Teen screen time crisis: what netflix’s ‘adolescence’ wants you to know Teen Screen Time Crisis: What Netflix’s ‘Adolescence’ Wants You to Know
Next Article Unusual bird migration patterns in the us midwest: what’s going on? Unusual Bird Migration Patterns in the US Midwest: What’s Going On?
Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Your Trusted Source for Accurate and Timely Updates!

Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.
FacebookLike
XFollow
RSS FeedFollow
Ad image

You Might Also Like

Website image 2025 08 11t111817. 036
BusinessEconomy

Stock Market Today: Nifty50 and Sensex Start the Week in Green — Track Updates and Key Market Trends

By
Ankita Das
Website image 2025 08 07t185133. 970
WorldBusiness

Vladimir Putin to Visit India by End of 2025, Confirms NSA Ajit Doval

By
Ankita Das
Mcgraw hill
Business

Publisher McGraw Hill to Go Public with $4.2 Billion Valuation on NYSE

By
Dolon Mondal
Mca slaps fine on nithin kamath zerodha amc for delay in appointing cfo infomance
BlogBusinessEconomyMoney Matters

Zerodha CEO Nithin Kamath Warns: “If This Share Market Crash Continues, Govt Will Step In”

By
admin
Ad image

About US


Brink’s Report delivers fresh, unbiased, and engaging content across politics, business, tech, entertainment, and more. From breaking news to deep dives, we keep you informed—and intrigued—with accurate reporting and diverse perspectives. Explore the world, one story at a time.

Top Categories
  • World
  • Business
  • Economy
  • Technology
Usefull Links
  • Contact Us
  • About Us
  • Privacy Policy
  • DMCA

© 2024-2025 Brinks Report. All content, including text, images, and other media, is copyrighted.